durvalumab plus etoposide and platin (n=268) vs. etoposide plus platin (n=269)
randomized controlled trial
durvalumab, etoposide plus either cisplatin or carboplatin
durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks, associated with
etoposide plus either cisplatin or carboplatin
up to six cycles of platinum-etoposide every 3 weeks plus prophylactic cranial irradiation (investigator's discretion) Platinum-etoposide consisted of etoposide 80-100 mg/m2 on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle)
all patients received etoposide plus either cisplatin or carboplatinIn /3 arms : durvalumab, with or without tremelimumab. Crossover from the platinum–etoposide to the immunotherapy plus platinum–etoposide groups was not allowed.
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
no specific information about EGFR or ALK status at inclusion
open-label
209 sites in 23 countries across Europe, Asia, North America, and South America
P3/ two sided and one interim analysi. Hierarchical multiple testing procedure with an α-exhaustive recycling strategy (OS/D : 4% and OS/DT 1% (recycle OS D)) then hierarchical testing with PFS/D and then PDS/DT
Durvalumab without tremelimumab plus platinum–etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group.